These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 11428736

  • 1. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms.
    Lanier BQ, Gross RD, Marks BB, Cockrum PC, Juniper EF.
    Ann Allergy Asthma Immunol; 2001 Jun; 86(6):641-8. PubMed ID: 11428736
    [Abstract] [Full Text] [Related]

  • 2. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model.
    Abelson MB, Lanier RQ.
    Acta Ophthalmol Scand Suppl; 1999 Jun; (228):53-6. PubMed ID: 10337434
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
    Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV, Bensch G.
    Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
    Avunduk AM, Tekelioglu Y, Turk A, Akyol N.
    Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
    [Abstract] [Full Text] [Related]

  • 5. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
    Abelson MB, Greiner JV.
    Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
    [Abstract] [Full Text] [Related]

  • 6. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
    Greiner JV, Udell IJ.
    Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
    Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek SS.
    Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
    [Abstract] [Full Text] [Related]

  • 8. Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy.
    Berger W, Abelson MB, Gomes PJ, Beck M, Kimura S, Westbrook T, Storms W, Galant S.
    Ann Allergy Asthma Immunol; 2005 Oct; 95(4):361-71. PubMed ID: 16279567
    [Abstract] [Full Text] [Related]

  • 9. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis.
    Abelson MB, Turner D.
    Clin Ther; 2003 Mar; 25(3):931-47. PubMed ID: 12852709
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model.
    Abelson MB.
    Ann Allergy Asthma Immunol; 1998 Sep; 81(3):211-8. PubMed ID: 9759796
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference.
    Leonardi A, Zafirakis P.
    Curr Med Res Opin; 2004 Aug; 20(8):1167-73. PubMed ID: 15324519
    [Abstract] [Full Text] [Related]

  • 12. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis.
    Katelaris CH, Ciprandi G, Missotten L, Turner FD, Bertin D, Berdeaux G, International Olopatadine Study Group.
    Clin Ther; 2002 Oct; 24(10):1561-75. PubMed ID: 12462286
    [Abstract] [Full Text] [Related]

  • 13. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
    Crampton HJ.
    Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
    [Abstract] [Full Text] [Related]

  • 14. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model.
    Abelson MB, Welch DL.
    Acta Ophthalmol Scand Suppl; 2000 Jul; (230):60-3. PubMed ID: 11057354
    [Abstract] [Full Text] [Related]

  • 15. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial.
    Meltzer EO, Malmstrom K, Lu S, Prenner BM, Wei LX, Weinstein SF, Wolfe JD, Reiss TF.
    J Allergy Clin Immunol; 2000 May; 105(5):917-22. PubMed ID: 10808172
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis.
    Meltzer EO, Hampel FC, Ratner PH, Bernstein DI, Larsen LV, Berger WE, Finn AF, Marple BF, Roland PS, Wall GM, Brubaker MJ, Dimas C, Potts SL, Silver LH, Barnes JR.
    Ann Allergy Asthma Immunol; 2005 Dec; 95(6):600-6. PubMed ID: 16400902
    [Abstract] [Full Text] [Related]

  • 17. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.
    Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC.
    Clin Ther; 2000 Jul; 22(7):826-33. PubMed ID: 10945509
    [Abstract] [Full Text] [Related]

  • 18. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis.
    Abelson MB, Gomes PJ, Vogelson CT, Pasquine TA, Turner FD, Wells DT, Robertson SM.
    Curr Med Res Opin; 2005 May; 21(5):683-91. PubMed ID: 15969867
    [Abstract] [Full Text] [Related]

  • 19. Triamcinolone acetonide aqueous nasal spray versus loratadine in seasonal allergic rhinitis: efficacy and quality of life.
    Condemi J, Schulz R, Lim J.
    Ann Allergy Asthma Immunol; 2000 May; 84(5):533-8. PubMed ID: 10831008
    [Abstract] [Full Text] [Related]

  • 20. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
    Spangler DL, Abelson MB, Ober A, Gotnes PJ.
    Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.